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Although the relationship between markers of disordered
mineral metabolism and cardiovascular mortality is established,
the relationship with sudden cardiac death (SCD) is less clear.
Karnik et al.5 found that hemodialysis patients who experi-
enced a witnessed cardiac arrest had lower serum phosphorus
levels than population controls, and we previously reported no
signiﬁcant relationship between serum calcium, phosphorus
and PTH levels, and survival following a witnessed peridialytic
cardiac arrest.6 Prospective randomized studies are needed to
examine the effect of current therapeutic options for abnormal
mineral metabolism and cardiovascular beneﬁt, including SCD.
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To the Editor: We read with interest the recent article by
Kusaba et al.1 The authors found that both recognition and
detection thresholds were increased in patients with chronic
kidney disease (CKD). They also found that patients with
diabetic nephropathy had a higher detection threshold than
non-diabetic patients with CKD. In this regard, one has to
consider the taste disturbance caused by angiotensin-
converting enzyme inhibitors (ACEIs) and angiotensin-2
receptor blockers (ARBs).2,3 The authors reported that ACEIs
and/or ARBs were prescribed for 72% of the patients with
CKD. This could explain the higher taste thresholds in CKD.
Similarly, it should be noted that ACEIs and/or ARBs are
more likely to be prescribed for patients with diabetic
nephropathy than for patients without diabetes mellitus.
Although the authors stated no difference in taste thresholds
based on the administration of antihypertensives except for
diuretics, the numbers obtained by comparison (22 versus 7)
do not yield enough statistical power. Therefore, we are
concerned about the effects of ACEIs and/or ARBs mentioned
in the study.
It is of interest that the recognition threshold for salty taste
was recovered after 1 week of sodium restriction. This
recovery may be unrelated to ACEI and/or ARB use. The
authors should clarify whether there was a change in ACEI
and/or ARB use during the 1 week of sodium restriction.
That there was no signiﬁcant difference in discrimination
threshold between before and after the sodium restriction
may be due to ACEI and/or ARB use. Further studies without
ACEI and ARB use are therefore warranted.
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The Authors Reply: We appreciate the interest of Drs
Ebihara and Kohzuki1 regarding our paper.2 We present here
our reply per their request.
First, regarding the effect of angiotensin-converting enzyme
inhibitors (ACEIs) and angiotensin-2 receptor blockers
(ARBs) on taste disturbance, these drugs were administered
to 21 patients (72%) in our study. We further analyzed the
effects of these drugs, which revealed that the recognition
threshold for salty taste was 0.91±0.31% for patients who
were administered these drugs and 0.80±0.11% for those who
Table 1 | Baseline characteristics of the study cohort
GFR X60 GFR 15–59 GFR o15
Number 14,652 4364 424
Median calcium (mg/dl) 8.7 8.7 8.8
No. of subjects with data (%) 2618 (18%) 809 (19%) 196 (46%)
Median phosphorus (mg/dl) 3.3 3.6 5.0
No. of subjects with data (%) 2504 (17%) 782 (18%) 203 (48%)
Calciumphosphorus 29 31 46
No. of subjects with data (%) 2424 (17%) 750 (17%) 195 (46%)
Abbreviation: GFR, glomerular filtration rate.
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